Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
161,353
archived clinical trials in
Cancer

An Investigational Drug, PF-02341066, Is Being Studied In Patients With Advanced Non-Small Cell Lung Cancer With A Specific Gene Profile Involving The Anaplastic Lymphoma Kinase (ALK) Gene
Phase 2, Open-Label Single Arm Study Of The Efficacy And Safety Of PF-02341066 In Patients With Advanced Non-Small Cell Lung Cancer (NSCLC) Harboring A Translocation Or Inversion Involving The Anaplastic Lymphoma Kinase (ALK) Gene Locus
Status: Enrolling
Updated:  2/5/2016
Karmanos Cancer Institute
mi
from
Detroit, MI
An Investigational Drug, PF-02341066, Is Being Studied In Patients With Advanced Non-Small Cell Lung Cancer With A Specific Gene Profile Involving The Anaplastic Lymphoma Kinase (ALK) Gene
Phase 2, Open-Label Single Arm Study Of The Efficacy And Safety Of PF-02341066 In Patients With Advanced Non-Small Cell Lung Cancer (NSCLC) Harboring A Translocation Or Inversion Involving The Anaplastic Lymphoma Kinase (ALK) Gene Locus
Status: Enrolling
Updated: 2/5/2016
Karmanos Cancer Institute
mi
from
Detroit, MI
Click here to add this to my saved trials
An Investigational Drug, PF-02341066, Is Being Studied In Patients With Advanced Non-Small Cell Lung Cancer With A Specific Gene Profile Involving The Anaplastic Lymphoma Kinase (ALK) Gene
Phase 2, Open-Label Single Arm Study Of The Efficacy And Safety Of PF-02341066 In Patients With Advanced Non-Small Cell Lung Cancer (NSCLC) Harboring A Translocation Or Inversion Involving The Anaplastic Lymphoma Kinase (ALK) Gene Locus
Status: Enrolling
Updated:  2/5/2016
Karmanos Cancer lnstitute at Farmington Hllls
mi
from
Farmington Hills, MI
An Investigational Drug, PF-02341066, Is Being Studied In Patients With Advanced Non-Small Cell Lung Cancer With A Specific Gene Profile Involving The Anaplastic Lymphoma Kinase (ALK) Gene
Phase 2, Open-Label Single Arm Study Of The Efficacy And Safety Of PF-02341066 In Patients With Advanced Non-Small Cell Lung Cancer (NSCLC) Harboring A Translocation Or Inversion Involving The Anaplastic Lymphoma Kinase (ALK) Gene Locus
Status: Enrolling
Updated: 2/5/2016
Karmanos Cancer lnstitute at Farmington Hllls
mi
from
Farmington Hills, MI
Click here to add this to my saved trials
An Investigational Drug, PF-02341066, Is Being Studied In Patients With Advanced Non-Small Cell Lung Cancer With A Specific Gene Profile Involving The Anaplastic Lymphoma Kinase (ALK) Gene
Phase 2, Open-Label Single Arm Study Of The Efficacy And Safety Of PF-02341066 In Patients With Advanced Non-Small Cell Lung Cancer (NSCLC) Harboring A Translocation Or Inversion Involving The Anaplastic Lymphoma Kinase (ALK) Gene Locus
Status: Enrolling
Updated:  2/5/2016
Washington University School of Medicine
mi
from
St. Louis, MO
An Investigational Drug, PF-02341066, Is Being Studied In Patients With Advanced Non-Small Cell Lung Cancer With A Specific Gene Profile Involving The Anaplastic Lymphoma Kinase (ALK) Gene
Phase 2, Open-Label Single Arm Study Of The Efficacy And Safety Of PF-02341066 In Patients With Advanced Non-Small Cell Lung Cancer (NSCLC) Harboring A Translocation Or Inversion Involving The Anaplastic Lymphoma Kinase (ALK) Gene Locus
Status: Enrolling
Updated: 2/5/2016
Washington University School of Medicine
mi
from
St. Louis, MO
Click here to add this to my saved trials
An Investigational Drug, PF-02341066, Is Being Studied In Patients With Advanced Non-Small Cell Lung Cancer With A Specific Gene Profile Involving The Anaplastic Lymphoma Kinase (ALK) Gene
Phase 2, Open-Label Single Arm Study Of The Efficacy And Safety Of PF-02341066 In Patients With Advanced Non-Small Cell Lung Cancer (NSCLC) Harboring A Translocation Or Inversion Involving The Anaplastic Lymphoma Kinase (ALK) Gene Locus
Status: Enrolling
Updated:  2/5/2016
Memorial Sloan Kettering Cancer Center
mi
from
New York, NY
An Investigational Drug, PF-02341066, Is Being Studied In Patients With Advanced Non-Small Cell Lung Cancer With A Specific Gene Profile Involving The Anaplastic Lymphoma Kinase (ALK) Gene
Phase 2, Open-Label Single Arm Study Of The Efficacy And Safety Of PF-02341066 In Patients With Advanced Non-Small Cell Lung Cancer (NSCLC) Harboring A Translocation Or Inversion Involving The Anaplastic Lymphoma Kinase (ALK) Gene Locus
Status: Enrolling
Updated: 2/5/2016
Memorial Sloan Kettering Cancer Center
mi
from
New York, NY
Click here to add this to my saved trials
An Investigational Drug, PF-02341066, Is Being Studied In Patients With Advanced Non-Small Cell Lung Cancer With A Specific Gene Profile Involving The Anaplastic Lymphoma Kinase (ALK) Gene
Phase 2, Open-Label Single Arm Study Of The Efficacy And Safety Of PF-02341066 In Patients With Advanced Non-Small Cell Lung Cancer (NSCLC) Harboring A Translocation Or Inversion Involving The Anaplastic Lymphoma Kinase (ALK) Gene Locus
Status: Enrolling
Updated:  2/5/2016
Oregon Health and Science University
mi
from
Portland, OR
An Investigational Drug, PF-02341066, Is Being Studied In Patients With Advanced Non-Small Cell Lung Cancer With A Specific Gene Profile Involving The Anaplastic Lymphoma Kinase (ALK) Gene
Phase 2, Open-Label Single Arm Study Of The Efficacy And Safety Of PF-02341066 In Patients With Advanced Non-Small Cell Lung Cancer (NSCLC) Harboring A Translocation Or Inversion Involving The Anaplastic Lymphoma Kinase (ALK) Gene Locus
Status: Enrolling
Updated: 2/5/2016
Oregon Health and Science University
mi
from
Portland, OR
Click here to add this to my saved trials
An Investigational Drug, PF-02341066, Is Being Studied In Patients With Advanced Non-Small Cell Lung Cancer With A Specific Gene Profile Involving The Anaplastic Lymphoma Kinase (ALK) Gene
Phase 2, Open-Label Single Arm Study Of The Efficacy And Safety Of PF-02341066 In Patients With Advanced Non-Small Cell Lung Cancer (NSCLC) Harboring A Translocation Or Inversion Involving The Anaplastic Lymphoma Kinase (ALK) Gene Locus
Status: Enrolling
Updated:  2/5/2016
Fox Chase Cancer Center
mi
from
Philadelphia, PA
An Investigational Drug, PF-02341066, Is Being Studied In Patients With Advanced Non-Small Cell Lung Cancer With A Specific Gene Profile Involving The Anaplastic Lymphoma Kinase (ALK) Gene
Phase 2, Open-Label Single Arm Study Of The Efficacy And Safety Of PF-02341066 In Patients With Advanced Non-Small Cell Lung Cancer (NSCLC) Harboring A Translocation Or Inversion Involving The Anaplastic Lymphoma Kinase (ALK) Gene Locus
Status: Enrolling
Updated: 2/5/2016
Fox Chase Cancer Center
mi
from
Philadelphia, PA
Click here to add this to my saved trials
An Investigational Drug, PF-02341066, Is Being Studied In Patients With Advanced Non-Small Cell Lung Cancer With A Specific Gene Profile Involving The Anaplastic Lymphoma Kinase (ALK) Gene
Phase 2, Open-Label Single Arm Study Of The Efficacy And Safety Of PF-02341066 In Patients With Advanced Non-Small Cell Lung Cancer (NSCLC) Harboring A Translocation Or Inversion Involving The Anaplastic Lymphoma Kinase (ALK) Gene Locus
Status: Enrolling
Updated:  2/5/2016
Chris O'Brien Lifehouse
mi
from
Camperdown,
An Investigational Drug, PF-02341066, Is Being Studied In Patients With Advanced Non-Small Cell Lung Cancer With A Specific Gene Profile Involving The Anaplastic Lymphoma Kinase (ALK) Gene
Phase 2, Open-Label Single Arm Study Of The Efficacy And Safety Of PF-02341066 In Patients With Advanced Non-Small Cell Lung Cancer (NSCLC) Harboring A Translocation Or Inversion Involving The Anaplastic Lymphoma Kinase (ALK) Gene Locus
Status: Enrolling
Updated: 2/5/2016
Chris O'Brien Lifehouse
mi
from
Camperdown,
Click here to add this to my saved trials
Brentuximab Vedotin in Patients With CD30-positive Nonlymphomatous Malignancies
A Phase 2, Open-label Study of Brentuximab Vedotin in Patients With CD30-positive Nonlymphomatous Malignancies
Status: Enrolling
Updated:  2/5/2016
University of Alabama at Birmingham
mi
from
Birmingham, AL
Brentuximab Vedotin in Patients With CD30-positive Nonlymphomatous Malignancies
A Phase 2, Open-label Study of Brentuximab Vedotin in Patients With CD30-positive Nonlymphomatous Malignancies
Status: Enrolling
Updated: 2/5/2016
University of Alabama at Birmingham
mi
from
Birmingham, AL
Click here to add this to my saved trials
Brentuximab Vedotin in Patients With CD30-positive Nonlymphomatous Malignancies
A Phase 2, Open-label Study of Brentuximab Vedotin in Patients With CD30-positive Nonlymphomatous Malignancies
Status: Enrolling
Updated:  2/5/2016
PMK Medical Group, Inc., dba Ventura County Hematology Oncology Specialists
mi
from
Oxnard, CA
Brentuximab Vedotin in Patients With CD30-positive Nonlymphomatous Malignancies
A Phase 2, Open-label Study of Brentuximab Vedotin in Patients With CD30-positive Nonlymphomatous Malignancies
Status: Enrolling
Updated: 2/5/2016
PMK Medical Group, Inc., dba Ventura County Hematology Oncology Specialists
mi
from
Oxnard, CA
Click here to add this to my saved trials
Brentuximab Vedotin in Patients With CD30-positive Nonlymphomatous Malignancies
A Phase 2, Open-label Study of Brentuximab Vedotin in Patients With CD30-positive Nonlymphomatous Malignancies
Status: Enrolling
Updated:  2/5/2016
Rocky Mountain Cancer Centers - Aurora
mi
from
Aurora, CO
Brentuximab Vedotin in Patients With CD30-positive Nonlymphomatous Malignancies
A Phase 2, Open-label Study of Brentuximab Vedotin in Patients With CD30-positive Nonlymphomatous Malignancies
Status: Enrolling
Updated: 2/5/2016
Rocky Mountain Cancer Centers - Aurora
mi
from
Aurora, CO
Click here to add this to my saved trials
Brentuximab Vedotin in Patients With CD30-positive Nonlymphomatous Malignancies
A Phase 2, Open-label Study of Brentuximab Vedotin in Patients With CD30-positive Nonlymphomatous Malignancies
Status: Enrolling
Updated:  2/5/2016
Mayo Clinic Cancer Center
mi
from
Jacksonville, FL
Brentuximab Vedotin in Patients With CD30-positive Nonlymphomatous Malignancies
A Phase 2, Open-label Study of Brentuximab Vedotin in Patients With CD30-positive Nonlymphomatous Malignancies
Status: Enrolling
Updated: 2/5/2016
Mayo Clinic Cancer Center
mi
from
Jacksonville, FL
Click here to add this to my saved trials
Brentuximab Vedotin in Patients With CD30-positive Nonlymphomatous Malignancies
A Phase 2, Open-label Study of Brentuximab Vedotin in Patients With CD30-positive Nonlymphomatous Malignancies
Status: Enrolling
Updated:  2/5/2016
Ocala Oncology Center
mi
from
Ocala, FL
Brentuximab Vedotin in Patients With CD30-positive Nonlymphomatous Malignancies
A Phase 2, Open-label Study of Brentuximab Vedotin in Patients With CD30-positive Nonlymphomatous Malignancies
Status: Enrolling
Updated: 2/5/2016
Ocala Oncology Center
mi
from
Ocala, FL
Click here to add this to my saved trials
Brentuximab Vedotin in Patients With CD30-positive Nonlymphomatous Malignancies
A Phase 2, Open-label Study of Brentuximab Vedotin in Patients With CD30-positive Nonlymphomatous Malignancies
Status: Enrolling
Updated:  2/5/2016
Dana-Farber Cancer Institute
mi
from
Boston, MA
Brentuximab Vedotin in Patients With CD30-positive Nonlymphomatous Malignancies
A Phase 2, Open-label Study of Brentuximab Vedotin in Patients With CD30-positive Nonlymphomatous Malignancies
Status: Enrolling
Updated: 2/5/2016
Dana-Farber Cancer Institute
mi
from
Boston, MA
Click here to add this to my saved trials
Brentuximab Vedotin in Patients With CD30-positive Nonlymphomatous Malignancies
A Phase 2, Open-label Study of Brentuximab Vedotin in Patients With CD30-positive Nonlymphomatous Malignancies
Status: Enrolling
Updated:  2/5/2016
Minnesota Oncology and Hematology, PA
mi
from
Minneapolis, MN
Brentuximab Vedotin in Patients With CD30-positive Nonlymphomatous Malignancies
A Phase 2, Open-label Study of Brentuximab Vedotin in Patients With CD30-positive Nonlymphomatous Malignancies
Status: Enrolling
Updated: 2/5/2016
Minnesota Oncology and Hematology, PA
mi
from
Minneapolis, MN
Click here to add this to my saved trials
Brentuximab Vedotin in Patients With CD30-positive Nonlymphomatous Malignancies
A Phase 2, Open-label Study of Brentuximab Vedotin in Patients With CD30-positive Nonlymphomatous Malignancies
Status: Enrolling
Updated:  2/5/2016
New York Oncology Hematology PC
mi
from
Albany, NY
Brentuximab Vedotin in Patients With CD30-positive Nonlymphomatous Malignancies
A Phase 2, Open-label Study of Brentuximab Vedotin in Patients With CD30-positive Nonlymphomatous Malignancies
Status: Enrolling
Updated: 2/5/2016
New York Oncology Hematology PC
mi
from
Albany, NY
Click here to add this to my saved trials
Brentuximab Vedotin in Patients With CD30-positive Nonlymphomatous Malignancies
A Phase 2, Open-label Study of Brentuximab Vedotin in Patients With CD30-positive Nonlymphomatous Malignancies
Status: Enrolling
Updated:  2/5/2016
Willamette Valley Cancer and Research / USOR
mi
from
Eugene, OR
Brentuximab Vedotin in Patients With CD30-positive Nonlymphomatous Malignancies
A Phase 2, Open-label Study of Brentuximab Vedotin in Patients With CD30-positive Nonlymphomatous Malignancies
Status: Enrolling
Updated: 2/5/2016
Willamette Valley Cancer and Research / USOR
mi
from
Eugene, OR
Click here to add this to my saved trials
Brentuximab Vedotin in Patients With CD30-positive Nonlymphomatous Malignancies
A Phase 2, Open-label Study of Brentuximab Vedotin in Patients With CD30-positive Nonlymphomatous Malignancies
Status: Enrolling
Updated:  2/5/2016
Northwest Cancer Specialists, P.C.
mi
from
Tulatin, OR
Brentuximab Vedotin in Patients With CD30-positive Nonlymphomatous Malignancies
A Phase 2, Open-label Study of Brentuximab Vedotin in Patients With CD30-positive Nonlymphomatous Malignancies
Status: Enrolling
Updated: 2/5/2016
Northwest Cancer Specialists, P.C.
mi
from
Tulatin, OR
Click here to add this to my saved trials
Brentuximab Vedotin in Patients With CD30-positive Nonlymphomatous Malignancies
A Phase 2, Open-label Study of Brentuximab Vedotin in Patients With CD30-positive Nonlymphomatous Malignancies
Status: Enrolling
Updated:  2/5/2016
St. Francis Hospital
mi
from
Greenville, SC
Brentuximab Vedotin in Patients With CD30-positive Nonlymphomatous Malignancies
A Phase 2, Open-label Study of Brentuximab Vedotin in Patients With CD30-positive Nonlymphomatous Malignancies
Status: Enrolling
Updated: 2/5/2016
St. Francis Hospital
mi
from
Greenville, SC
Click here to add this to my saved trials
Brentuximab Vedotin in Patients With CD30-positive Nonlymphomatous Malignancies
A Phase 2, Open-label Study of Brentuximab Vedotin in Patients With CD30-positive Nonlymphomatous Malignancies
Status: Enrolling
Updated:  2/5/2016
Texas Oncology, P.A. - Bedford
mi
from
Bedford, TX
Brentuximab Vedotin in Patients With CD30-positive Nonlymphomatous Malignancies
A Phase 2, Open-label Study of Brentuximab Vedotin in Patients With CD30-positive Nonlymphomatous Malignancies
Status: Enrolling
Updated: 2/5/2016
Texas Oncology, P.A. - Bedford
mi
from
Bedford, TX
Click here to add this to my saved trials
Brentuximab Vedotin in Patients With CD30-positive Nonlymphomatous Malignancies
A Phase 2, Open-label Study of Brentuximab Vedotin in Patients With CD30-positive Nonlymphomatous Malignancies
Status: Enrolling
Updated:  2/5/2016
Texas Oncology - Medical City Dallas
mi
from
Dallas, TX
Brentuximab Vedotin in Patients With CD30-positive Nonlymphomatous Malignancies
A Phase 2, Open-label Study of Brentuximab Vedotin in Patients With CD30-positive Nonlymphomatous Malignancies
Status: Enrolling
Updated: 2/5/2016
Texas Oncology - Medical City Dallas
mi
from
Dallas, TX
Click here to add this to my saved trials
Brentuximab Vedotin in Patients With CD30-positive Nonlymphomatous Malignancies
A Phase 2, Open-label Study of Brentuximab Vedotin in Patients With CD30-positive Nonlymphomatous Malignancies
Status: Enrolling
Updated:  2/5/2016
Texas Oncology-Dallas, PA Presbyterian
mi
from
Dallas, TX
Brentuximab Vedotin in Patients With CD30-positive Nonlymphomatous Malignancies
A Phase 2, Open-label Study of Brentuximab Vedotin in Patients With CD30-positive Nonlymphomatous Malignancies
Status: Enrolling
Updated: 2/5/2016
Texas Oncology-Dallas, PA Presbyterian
mi
from
Dallas, TX
Click here to add this to my saved trials
Brentuximab Vedotin in Patients With CD30-positive Nonlymphomatous Malignancies
A Phase 2, Open-label Study of Brentuximab Vedotin in Patients With CD30-positive Nonlymphomatous Malignancies
Status: Enrolling
Updated:  2/5/2016
Texas Oncology- Denton South
mi
from
Denton, TX
Brentuximab Vedotin in Patients With CD30-positive Nonlymphomatous Malignancies
A Phase 2, Open-label Study of Brentuximab Vedotin in Patients With CD30-positive Nonlymphomatous Malignancies
Status: Enrolling
Updated: 2/5/2016
Texas Oncology- Denton South
mi
from
Denton, TX
Click here to add this to my saved trials
Brentuximab Vedotin in Patients With CD30-positive Nonlymphomatous Malignancies
A Phase 2, Open-label Study of Brentuximab Vedotin in Patients With CD30-positive Nonlymphomatous Malignancies
Status: Enrolling
Updated:  2/5/2016
Texas Oncology- Fort Worth - 12th Avenue
mi
from
Fort Worth, TX
Brentuximab Vedotin in Patients With CD30-positive Nonlymphomatous Malignancies
A Phase 2, Open-label Study of Brentuximab Vedotin in Patients With CD30-positive Nonlymphomatous Malignancies
Status: Enrolling
Updated: 2/5/2016
Texas Oncology- Fort Worth - 12th Avenue
mi
from
Fort Worth, TX
Click here to add this to my saved trials
Brentuximab Vedotin in Patients With CD30-positive Nonlymphomatous Malignancies
A Phase 2, Open-label Study of Brentuximab Vedotin in Patients With CD30-positive Nonlymphomatous Malignancies
Status: Enrolling
Updated:  2/5/2016
MD Anderson Cancer Center Leukemia Group
mi
from
Houston, TX
Brentuximab Vedotin in Patients With CD30-positive Nonlymphomatous Malignancies
A Phase 2, Open-label Study of Brentuximab Vedotin in Patients With CD30-positive Nonlymphomatous Malignancies
Status: Enrolling
Updated: 2/5/2016
MD Anderson Cancer Center Leukemia Group
mi
from
Houston, TX
Click here to add this to my saved trials
Brentuximab Vedotin in Patients With CD30-positive Nonlymphomatous Malignancies
A Phase 2, Open-label Study of Brentuximab Vedotin in Patients With CD30-positive Nonlymphomatous Malignancies
Status: Enrolling
Updated:  2/5/2016
M.D. Anderson Cancer Center at University of Texas
mi
from
Houston, TX
Brentuximab Vedotin in Patients With CD30-positive Nonlymphomatous Malignancies
A Phase 2, Open-label Study of Brentuximab Vedotin in Patients With CD30-positive Nonlymphomatous Malignancies
Status: Enrolling
Updated: 2/5/2016
M.D. Anderson Cancer Center at University of Texas
mi
from
Houston, TX
Click here to add this to my saved trials
Brentuximab Vedotin in Patients With CD30-positive Nonlymphomatous Malignancies
A Phase 2, Open-label Study of Brentuximab Vedotin in Patients With CD30-positive Nonlymphomatous Malignancies
Status: Enrolling
Updated:  2/5/2016
Texas Oncology - Central Austin Cancer Center
mi
from
Round Rock, TX
Brentuximab Vedotin in Patients With CD30-positive Nonlymphomatous Malignancies
A Phase 2, Open-label Study of Brentuximab Vedotin in Patients With CD30-positive Nonlymphomatous Malignancies
Status: Enrolling
Updated: 2/5/2016
Texas Oncology - Central Austin Cancer Center
mi
from
Round Rock, TX
Click here to add this to my saved trials
Brentuximab Vedotin in Patients With CD30-positive Nonlymphomatous Malignancies
A Phase 2, Open-label Study of Brentuximab Vedotin in Patients With CD30-positive Nonlymphomatous Malignancies
Status: Enrolling
Updated:  2/5/2016
Cancer Centers of South Texas - HOAST
mi
from
San Antonio, TX
Brentuximab Vedotin in Patients With CD30-positive Nonlymphomatous Malignancies
A Phase 2, Open-label Study of Brentuximab Vedotin in Patients With CD30-positive Nonlymphomatous Malignancies
Status: Enrolling
Updated: 2/5/2016
Cancer Centers of South Texas - HOAST
mi
from
San Antonio, TX
Click here to add this to my saved trials
Brentuximab Vedotin in Patients With CD30-positive Nonlymphomatous Malignancies
A Phase 2, Open-label Study of Brentuximab Vedotin in Patients With CD30-positive Nonlymphomatous Malignancies
Status: Enrolling
Updated:  2/5/2016
Texas Oncology-Waco
mi
from
Waco, TX
Brentuximab Vedotin in Patients With CD30-positive Nonlymphomatous Malignancies
A Phase 2, Open-label Study of Brentuximab Vedotin in Patients With CD30-positive Nonlymphomatous Malignancies
Status: Enrolling
Updated: 2/5/2016
Texas Oncology-Waco
mi
from
Waco, TX
Click here to add this to my saved trials
Brentuximab Vedotin in Patients With CD30-positive Nonlymphomatous Malignancies
A Phase 2, Open-label Study of Brentuximab Vedotin in Patients With CD30-positive Nonlymphomatous Malignancies
Status: Enrolling
Updated:  2/5/2016
Oncology and Hematology Assoc of SW VA DBA Blue Ridge Cancer Care
mi
from
Blacksburg, VA
Brentuximab Vedotin in Patients With CD30-positive Nonlymphomatous Malignancies
A Phase 2, Open-label Study of Brentuximab Vedotin in Patients With CD30-positive Nonlymphomatous Malignancies
Status: Enrolling
Updated: 2/5/2016
Oncology and Hematology Assoc of SW VA DBA Blue Ridge Cancer Care
mi
from
Blacksburg, VA
Click here to add this to my saved trials
Brentuximab Vedotin in Patients With CD30-positive Nonlymphomatous Malignancies
A Phase 2, Open-label Study of Brentuximab Vedotin in Patients With CD30-positive Nonlymphomatous Malignancies
Status: Enrolling
Updated:  2/5/2016
Virginia Cancer Specialists, PC
mi
from
Fairfax, VA
Brentuximab Vedotin in Patients With CD30-positive Nonlymphomatous Malignancies
A Phase 2, Open-label Study of Brentuximab Vedotin in Patients With CD30-positive Nonlymphomatous Malignancies
Status: Enrolling
Updated: 2/5/2016
Virginia Cancer Specialists, PC
mi
from
Fairfax, VA
Click here to add this to my saved trials
Brentuximab Vedotin in Patients With CD30-positive Nonlymphomatous Malignancies
A Phase 2, Open-label Study of Brentuximab Vedotin in Patients With CD30-positive Nonlymphomatous Malignancies
Status: Enrolling
Updated:  2/5/2016
Puget Sound Cancer Centers
mi
from
Edmonds, WA
Brentuximab Vedotin in Patients With CD30-positive Nonlymphomatous Malignancies
A Phase 2, Open-label Study of Brentuximab Vedotin in Patients With CD30-positive Nonlymphomatous Malignancies
Status: Enrolling
Updated: 2/5/2016
Puget Sound Cancer Centers
mi
from
Edmonds, WA
Click here to add this to my saved trials
Brentuximab Vedotin in Patients With CD30-positive Nonlymphomatous Malignancies
A Phase 2, Open-label Study of Brentuximab Vedotin in Patients With CD30-positive Nonlymphomatous Malignancies
Status: Enrolling
Updated:  2/5/2016
Cancer Care Northwest
mi
from
Spokane Valley, WA
Brentuximab Vedotin in Patients With CD30-positive Nonlymphomatous Malignancies
A Phase 2, Open-label Study of Brentuximab Vedotin in Patients With CD30-positive Nonlymphomatous Malignancies
Status: Enrolling
Updated: 2/5/2016
Cancer Care Northwest
mi
from
Spokane Valley, WA
Click here to add this to my saved trials
Brentuximab Vedotin in Patients With CD30-positive Nonlymphomatous Malignancies
A Phase 2, Open-label Study of Brentuximab Vedotin in Patients With CD30-positive Nonlymphomatous Malignancies
Status: Enrolling
Updated:  2/5/2016
City of Hope
mi
from
Duarte, CA
Brentuximab Vedotin in Patients With CD30-positive Nonlymphomatous Malignancies
A Phase 2, Open-label Study of Brentuximab Vedotin in Patients With CD30-positive Nonlymphomatous Malignancies
Status: Enrolling
Updated: 2/5/2016
City of Hope
mi
from
Duarte, CA
Click here to add this to my saved trials
Brentuximab Vedotin in Patients With CD30-positive Nonlymphomatous Malignancies
A Phase 2, Open-label Study of Brentuximab Vedotin in Patients With CD30-positive Nonlymphomatous Malignancies
Status: Enrolling
Updated:  2/5/2016
Indiana University Simon Cancer Center
mi
from
Indianapolis, IN
Brentuximab Vedotin in Patients With CD30-positive Nonlymphomatous Malignancies
A Phase 2, Open-label Study of Brentuximab Vedotin in Patients With CD30-positive Nonlymphomatous Malignancies
Status: Enrolling
Updated: 2/5/2016
Indiana University Simon Cancer Center
mi
from
Indianapolis, IN
Click here to add this to my saved trials
Brentuximab Vedotin in Patients With CD30-positive Nonlymphomatous Malignancies
A Phase 2, Open-label Study of Brentuximab Vedotin in Patients With CD30-positive Nonlymphomatous Malignancies
Status: Enrolling
Updated:  2/5/2016
University Hospitals at Case Medical Center
mi
from
Cleveland, OH
Brentuximab Vedotin in Patients With CD30-positive Nonlymphomatous Malignancies
A Phase 2, Open-label Study of Brentuximab Vedotin in Patients With CD30-positive Nonlymphomatous Malignancies
Status: Enrolling
Updated: 2/5/2016
University Hospitals at Case Medical Center
mi
from
Cleveland, OH
Click here to add this to my saved trials
Brentuximab Vedotin in Patients With CD30-positive Nonlymphomatous Malignancies
A Phase 2, Open-label Study of Brentuximab Vedotin in Patients With CD30-positive Nonlymphomatous Malignancies
Status: Enrolling
Updated:  2/5/2016
Yakima Valley Memorial Hospital/North Star Lodge
mi
from
Yakima, WA
Brentuximab Vedotin in Patients With CD30-positive Nonlymphomatous Malignancies
A Phase 2, Open-label Study of Brentuximab Vedotin in Patients With CD30-positive Nonlymphomatous Malignancies
Status: Enrolling
Updated: 2/5/2016
Yakima Valley Memorial Hospital/North Star Lodge
mi
from
Yakima, WA
Click here to add this to my saved trials
Study of the Effect of GTx-758 on Serum PSA and Testosterone in Men With Prostate Cancer
Phase II, Open Label Study of the Effect of GTx-758 as Secondary Hormonal Therapy on Serum PSA and Serum Free Testosterone Levels in Men With Metastatic Castration Resistant Prostate Cancer Maintained on Androgen Deprivation Therapy
Status: Enrolling
Updated:  2/5/2016
Urology Associates Medical Group
mi
from
Burbank, CA
Study of the Effect of GTx-758 on Serum PSA and Testosterone in Men With Prostate Cancer
Phase II, Open Label Study of the Effect of GTx-758 as Secondary Hormonal Therapy on Serum PSA and Serum Free Testosterone Levels in Men With Metastatic Castration Resistant Prostate Cancer Maintained on Androgen Deprivation Therapy
Status: Enrolling
Updated: 2/5/2016
Urology Associates Medical Group
mi
from
Burbank, CA
Click here to add this to my saved trials
Study of the Effect of GTx-758 on Serum PSA and Testosterone in Men With Prostate Cancer
Phase II, Open Label Study of the Effect of GTx-758 as Secondary Hormonal Therapy on Serum PSA and Serum Free Testosterone Levels in Men With Metastatic Castration Resistant Prostate Cancer Maintained on Androgen Deprivation Therapy
Status: Enrolling
Updated:  2/5/2016
Tower Urology
mi
from
Los Angeles, CA
Study of the Effect of GTx-758 on Serum PSA and Testosterone in Men With Prostate Cancer
Phase II, Open Label Study of the Effect of GTx-758 as Secondary Hormonal Therapy on Serum PSA and Serum Free Testosterone Levels in Men With Metastatic Castration Resistant Prostate Cancer Maintained on Androgen Deprivation Therapy
Status: Enrolling
Updated: 2/5/2016
Tower Urology
mi
from
Los Angeles, CA
Click here to add this to my saved trials
Study of the Effect of GTx-758 on Serum PSA and Testosterone in Men With Prostate Cancer
Phase II, Open Label Study of the Effect of GTx-758 as Secondary Hormonal Therapy on Serum PSA and Serum Free Testosterone Levels in Men With Metastatic Castration Resistant Prostate Cancer Maintained on Androgen Deprivation Therapy
Status: Enrolling
Updated:  2/5/2016
VA Greater Los Angeles
mi
from
Los Angeles, CA
Study of the Effect of GTx-758 on Serum PSA and Testosterone in Men With Prostate Cancer
Phase II, Open Label Study of the Effect of GTx-758 as Secondary Hormonal Therapy on Serum PSA and Serum Free Testosterone Levels in Men With Metastatic Castration Resistant Prostate Cancer Maintained on Androgen Deprivation Therapy
Status: Enrolling
Updated: 2/5/2016
VA Greater Los Angeles
mi
from
Los Angeles, CA
Click here to add this to my saved trials
Study of the Effect of GTx-758 on Serum PSA and Testosterone in Men With Prostate Cancer
Phase II, Open Label Study of the Effect of GTx-758 as Secondary Hormonal Therapy on Serum PSA and Serum Free Testosterone Levels in Men With Metastatic Castration Resistant Prostate Cancer Maintained on Androgen Deprivation Therapy
Status: Enrolling
Updated:  2/5/2016
San Bernardino Urological Assoc.
mi
from
San Bernardino, CA
Study of the Effect of GTx-758 on Serum PSA and Testosterone in Men With Prostate Cancer
Phase II, Open Label Study of the Effect of GTx-758 as Secondary Hormonal Therapy on Serum PSA and Serum Free Testosterone Levels in Men With Metastatic Castration Resistant Prostate Cancer Maintained on Androgen Deprivation Therapy
Status: Enrolling
Updated: 2/5/2016
San Bernardino Urological Assoc.
mi
from
San Bernardino, CA
Click here to add this to my saved trials
Study of the Effect of GTx-758 on Serum PSA and Testosterone in Men With Prostate Cancer
Phase II, Open Label Study of the Effect of GTx-758 as Secondary Hormonal Therapy on Serum PSA and Serum Free Testosterone Levels in Men With Metastatic Castration Resistant Prostate Cancer Maintained on Androgen Deprivation Therapy
Status: Enrolling
Updated:  2/5/2016
Genesis Healthcare Partners
mi
from
San Diego, CA
Study of the Effect of GTx-758 on Serum PSA and Testosterone in Men With Prostate Cancer
Phase II, Open Label Study of the Effect of GTx-758 as Secondary Hormonal Therapy on Serum PSA and Serum Free Testosterone Levels in Men With Metastatic Castration Resistant Prostate Cancer Maintained on Androgen Deprivation Therapy
Status: Enrolling
Updated: 2/5/2016
Genesis Healthcare Partners
mi
from
San Diego, CA
Click here to add this to my saved trials
Study of the Effect of GTx-758 on Serum PSA and Testosterone in Men With Prostate Cancer
Phase II, Open Label Study of the Effect of GTx-758 as Secondary Hormonal Therapy on Serum PSA and Serum Free Testosterone Levels in Men With Metastatic Castration Resistant Prostate Cancer Maintained on Androgen Deprivation Therapy
Status: Enrolling
Updated:  2/5/2016
Urology Specialists of So. California
mi
from
Torrance, CA
Study of the Effect of GTx-758 on Serum PSA and Testosterone in Men With Prostate Cancer
Phase II, Open Label Study of the Effect of GTx-758 as Secondary Hormonal Therapy on Serum PSA and Serum Free Testosterone Levels in Men With Metastatic Castration Resistant Prostate Cancer Maintained on Androgen Deprivation Therapy
Status: Enrolling
Updated: 2/5/2016
Urology Specialists of So. California
mi
from
Torrance, CA
Click here to add this to my saved trials
Study of the Effect of GTx-758 on Serum PSA and Testosterone in Men With Prostate Cancer
Phase II, Open Label Study of the Effect of GTx-758 as Secondary Hormonal Therapy on Serum PSA and Serum Free Testosterone Levels in Men With Metastatic Castration Resistant Prostate Cancer Maintained on Androgen Deprivation Therapy
Status: Enrolling
Updated:  2/5/2016
Connecticut Clinical Research Center, LLC
mi
from
Middlebury, CT
Study of the Effect of GTx-758 on Serum PSA and Testosterone in Men With Prostate Cancer
Phase II, Open Label Study of the Effect of GTx-758 as Secondary Hormonal Therapy on Serum PSA and Serum Free Testosterone Levels in Men With Metastatic Castration Resistant Prostate Cancer Maintained on Androgen Deprivation Therapy
Status: Enrolling
Updated: 2/5/2016
Connecticut Clinical Research Center, LLC
mi
from
Middlebury, CT
Click here to add this to my saved trials
Study of the Effect of GTx-758 on Serum PSA and Testosterone in Men With Prostate Cancer
Phase II, Open Label Study of the Effect of GTx-758 as Secondary Hormonal Therapy on Serum PSA and Serum Free Testosterone Levels in Men With Metastatic Castration Resistant Prostate Cancer Maintained on Androgen Deprivation Therapy
Status: Enrolling
Updated:  2/5/2016
So. Florida Medical Research
mi
from
Aventura, FL
Study of the Effect of GTx-758 on Serum PSA and Testosterone in Men With Prostate Cancer
Phase II, Open Label Study of the Effect of GTx-758 as Secondary Hormonal Therapy on Serum PSA and Serum Free Testosterone Levels in Men With Metastatic Castration Resistant Prostate Cancer Maintained on Androgen Deprivation Therapy
Status: Enrolling
Updated: 2/5/2016
So. Florida Medical Research
mi
from
Aventura, FL
Click here to add this to my saved trials
Study of the Effect of GTx-758 on Serum PSA and Testosterone in Men With Prostate Cancer
Phase II, Open Label Study of the Effect of GTx-758 as Secondary Hormonal Therapy on Serum PSA and Serum Free Testosterone Levels in Men With Metastatic Castration Resistant Prostate Cancer Maintained on Androgen Deprivation Therapy
Status: Enrolling
Updated:  2/5/2016
AMPM Research
mi
from
Miami, FL
Study of the Effect of GTx-758 on Serum PSA and Testosterone in Men With Prostate Cancer
Phase II, Open Label Study of the Effect of GTx-758 as Secondary Hormonal Therapy on Serum PSA and Serum Free Testosterone Levels in Men With Metastatic Castration Resistant Prostate Cancer Maintained on Androgen Deprivation Therapy
Status: Enrolling
Updated: 2/5/2016
AMPM Research
mi
from
Miami, FL
Click here to add this to my saved trials
Study of the Effect of GTx-758 on Serum PSA and Testosterone in Men With Prostate Cancer
Phase II, Open Label Study of the Effect of GTx-758 as Secondary Hormonal Therapy on Serum PSA and Serum Free Testosterone Levels in Men With Metastatic Castration Resistant Prostate Cancer Maintained on Androgen Deprivation Therapy
Status: Enrolling
Updated:  2/5/2016
Coastal Medical Center
mi
from
Sarasota, FL
Study of the Effect of GTx-758 on Serum PSA and Testosterone in Men With Prostate Cancer
Phase II, Open Label Study of the Effect of GTx-758 as Secondary Hormonal Therapy on Serum PSA and Serum Free Testosterone Levels in Men With Metastatic Castration Resistant Prostate Cancer Maintained on Androgen Deprivation Therapy
Status: Enrolling
Updated: 2/5/2016
Coastal Medical Center
mi
from
Sarasota, FL
Click here to add this to my saved trials
Study of the Effect of GTx-758 on Serum PSA and Testosterone in Men With Prostate Cancer
Phase II, Open Label Study of the Effect of GTx-758 as Secondary Hormonal Therapy on Serum PSA and Serum Free Testosterone Levels in Men With Metastatic Castration Resistant Prostate Cancer Maintained on Androgen Deprivation Therapy
Status: Enrolling
Updated:  2/5/2016
GTx Investigative Site
mi
from
St Petersburg, FL
Study of the Effect of GTx-758 on Serum PSA and Testosterone in Men With Prostate Cancer
Phase II, Open Label Study of the Effect of GTx-758 as Secondary Hormonal Therapy on Serum PSA and Serum Free Testosterone Levels in Men With Metastatic Castration Resistant Prostate Cancer Maintained on Androgen Deprivation Therapy
Status: Enrolling
Updated: 2/5/2016
GTx Investigative Site
mi
from
St Petersburg, FL
Click here to add this to my saved trials
Study of the Effect of GTx-758 on Serum PSA and Testosterone in Men With Prostate Cancer
Phase II, Open Label Study of the Effect of GTx-758 as Secondary Hormonal Therapy on Serum PSA and Serum Free Testosterone Levels in Men With Metastatic Castration Resistant Prostate Cancer Maintained on Androgen Deprivation Therapy
Status: Enrolling
Updated:  2/5/2016
Pinellas Urology Inc.
mi
from
St. Petersburg, FL
Study of the Effect of GTx-758 on Serum PSA and Testosterone in Men With Prostate Cancer
Phase II, Open Label Study of the Effect of GTx-758 as Secondary Hormonal Therapy on Serum PSA and Serum Free Testosterone Levels in Men With Metastatic Castration Resistant Prostate Cancer Maintained on Androgen Deprivation Therapy
Status: Enrolling
Updated: 2/5/2016
Pinellas Urology Inc.
mi
from
St. Petersburg, FL
Click here to add this to my saved trials
Study of the Effect of GTx-758 on Serum PSA and Testosterone in Men With Prostate Cancer
Phase II, Open Label Study of the Effect of GTx-758 as Secondary Hormonal Therapy on Serum PSA and Serum Free Testosterone Levels in Men With Metastatic Castration Resistant Prostate Cancer Maintained on Androgen Deprivation Therapy
Status: Enrolling
Updated:  2/5/2016
Urology of Indiana
mi
from
Greenwood, IN
Study of the Effect of GTx-758 on Serum PSA and Testosterone in Men With Prostate Cancer
Phase II, Open Label Study of the Effect of GTx-758 as Secondary Hormonal Therapy on Serum PSA and Serum Free Testosterone Levels in Men With Metastatic Castration Resistant Prostate Cancer Maintained on Androgen Deprivation Therapy
Status: Enrolling
Updated: 2/5/2016
Urology of Indiana
mi
from
Greenwood, IN
Click here to add this to my saved trials
Study of the Effect of GTx-758 on Serum PSA and Testosterone in Men With Prostate Cancer
Phase II, Open Label Study of the Effect of GTx-758 as Secondary Hormonal Therapy on Serum PSA and Serum Free Testosterone Levels in Men With Metastatic Castration Resistant Prostate Cancer Maintained on Androgen Deprivation Therapy
Status: Enrolling
Updated:  2/5/2016
First Urology PSC
mi
from
Jeffersonville, IN
Study of the Effect of GTx-758 on Serum PSA and Testosterone in Men With Prostate Cancer
Phase II, Open Label Study of the Effect of GTx-758 as Secondary Hormonal Therapy on Serum PSA and Serum Free Testosterone Levels in Men With Metastatic Castration Resistant Prostate Cancer Maintained on Androgen Deprivation Therapy
Status: Enrolling
Updated: 2/5/2016
First Urology PSC
mi
from
Jeffersonville, IN
Click here to add this to my saved trials